27 completed, 12 recruiting, 11 unknown, 4 active not recruiting. 20 Phase 3, 16 Not applicable, 6 Phase 4, 4 Phase 2.
Follow Episodic Migraine: new trials by email Literature Review of Episodic Migraine trials Research Report on Episodic Migraine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neurofeedback for Episodic Migraine Neurofeedback - Episodic Migraine | Not applicable | Not yet recruiting | University of Salamanca | 66 | 2026-11-15 | 2026-06-22 |
| Using Virtual Reality to Teach Mindfulness to People With Migraine ACT therapy delivered by REACT NeuroVR headset - Migraine Disorders, Migraine With Aura | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 160 | 2026-09-30 | 2026-09-30 |
| A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine Xeomin, Placebo - Episodic Migraine | Phase 3 | Active not recruiting | Merz Therapeutics GmbH | 997 | 2025-08-21 | 2026-10-14 |
| Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine Gou-Teng-San, Placebo - Episodic Migraine | Phase 3 | Recruiting | Tsai, Chueh-Yi, MD | 40 | 2025-07-01 | 2026-05-20 |
| Chiropractic Care for Episodic Migraine Chiropractic Care, Headache Health Education - Episodic Migraine | Not applicable | Recruiting | Brigham and Women's Hospital | 60 | 2025-03-22 | 2026-06-26 |
| Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine Atogepant 60 mg - Migraine Disorder, Episodic Migraine | Recruiting | IRCCS National Neurological Institute "C. Mondino" Foundation | 30 | 2024-12-01 | 2025-03-18 | |
| A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults Corabotase, Placebo, Corabotase dose A - Episodic Migraine, Chronic Migraine | Phase 2 | Active not recruiting | Ipsen | 670 | 2024-10-10 | 2026-09-08 |
| Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine Atogepant - Chronic Migraine, Episodic Migraine | Recruiting | AbbVie | 3000 | 2024-09-24 | 2026-07-22 | |
| Prophylactic Treatment With Atorvastatin for Episodic Migraine. Atorvastatin 40mg, Placebo, Atorvastatin 20mg - Episodic Migraine | Phase 2 | Recruiting | St. Olavs Hospital | 450 | 2024-05-01 | 2026-07-14 |
| Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine Greater occipital nerve blockade, Sphenopalatine ganglion blockade - Greater Occipital Nerve Block, Sphenopalatine Ganglion Block | Not applicable | Completed | New Valley University | 60 | 2024-05-01 | 2025-05-30 |
| Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine CGRP antibody or gepant - Migraine, Episodic Migraine | Recruiting | Hospital Universitari Vall d'Hebron Research Institute | 700 | 2024-01-02 | 2025-09-08 | |
| Mi-Helper Transnasal Cooling for Acute Treatment of Migraine Mi-Helper - Episodic Migraine, Migraine With Aura | Not applicable | Completed | CoolTech LLC | 172 | 2023-11-15 | 2024-09-26 |
| A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults Botulinum toxin type A, Placebo - Episodic Migraine | Phase 3 | Active not recruiting | Ipsen | 751 | 2023-09-29 | 2026-09-04 |
| Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) Click Digital Therapeutic - Migraine, Episodic Migraine | Phase 3 | Completed | Click Therapeutics, Inc. | 110 | 2023-07-21 | 2024-12-18 |
| Efficacy of Nerve Blocks for Episodic Migraine Bupivacaine HCl 0.5% Injectable Solution, Methylprednisolone 40 MG Injection - Episodic Migraine | Phase 2 | Recruiting | Mayo Clinic | 60 | 2023-07-10 | 2026-06-16 |
| A Study of Eptinezumab in Pediatric Participants With Episodic Migraine Eptinezumab, Placebo - Episodic Migraine | Phase 3 | Recruiting | H. Lundbeck A/S | 315 | 2023-06-08 | 2026-10-14 |
| Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments MAbs - Migraine Disorders, Chronic Migraine | Unknown | IRCCS National Neurological Institute "C. Mondino" Foundation | 100 | 2023-05-10 | 2024-08-20 | |
| Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments Palmitoyl ethanolamide, Ketogenic diet - Migraine Disorders, Chronic Migraine | Unknown | IRCCS National Neurological Institute "C. Mondino" Foundation | 45 | 2023-05-10 | 2024-08-20 | |
| Biochemical Profiling of Migraine Patients MAbs - Migraine Disorders, Chronic Migraine | Unknown | IRCCS National Neurological Institute "C. Mondino" Foundation | 100 | 2023-05-10 | 2024-09-05 | |
| A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine Atogepant, Placebo-Matching Atogepant - Episodic Migraine | Phase 3 | Recruiting | AbbVie | 450 | 2023-05-01 | 2026-10-06 |
Showing 20 of 59. Sign in to see all of them.
Migraine Disorders (31) · Headache (10) · Migraine with Aura (6) · Migraine without Aura (6) · Epilepsy (3) · Recurrence (2) · Headache Disorders (1) · Headache Disorders, Secondary (1) · Hyperacusis (1) · Joint Diseases (1) · Pain (1) · Photophobia (1) · Sleep Initiation and Maintenance Disorders (1)
Nervous System Diseases (32) · Brain Diseases (31) · Central Nervous System Diseases (31) · Headache Disorders, Primary (31) · Headache Disorders (30) · Neurologic Manifestations (11) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Pain (9) · Disease Attributes (2) · Pathologic Processes (2) · Dyssomnias (1) · Ear Diseases (1) · Eye Diseases (1) · Hearing Disorders (1)
atogepant (10) · galcanezumab (5) · erenumab (4) · Botulinum Toxins, Type A (3) · Ligands (3) · Biofeedback, Psychology (2) · Calcitonin Gene-Related Peptide Receptor Antagonists (2) · Lidocaine (2) · Standard of Care (2) · fremanezumab (2) · rimegepant sulfate (2) · Aspirin (1) · Atorvastatin (1) · Bupivacaine (1) · Diet, Ketogenic (1)
AbbVie (6) · IRCCS National Neurological Institute "C. Mondino" Foundation (5) · Allergan (4) · Eli Lilly and Company (3) · Brigham and Women's Hospital (2) · Click Therapeutics, Inc. (2) · CoolTech LLC (2) · Hospital Universitari Vall d'Hebron Research Institute (2) · Ipsen (2) · Novartis Pharmaceuticals (2) · Afyonkarahisar Health Sciences University (1) · Ain Shams University (1) · Amgen (1) · Austrian Migraine Registry Collaboration (1) · Beth Israel Deaconess Medical Center (1)
United States (33) · Italy (16) · Spain (14) · Germany (10) · Poland (10) · United Kingdom (9) · Canada (8) · Czechia (8) · France (8) · Denmark (6) · Netherlands (6) · Austria (5) · Argentina (4) · Japan (4) · Norway (4)
Joel Trugman, MD (3) · Anne H Aamodt, Senior researcher (1) · Armando Perrotta, MD (1) · Azliza Ibrahim, MMed (1) · Bendik S Winsvold, Post.doc. (1) · Christina L. Szperka, MD, MSCE (1) · Chun-Pai Yang, MD (1) · Cindy J. Fuller, Ph.D. (1)
PMID 33142014, PMID 33942560, PMID 38462625, PMID 39648629, PMID 30360965, PMID 35978286, PMID 38773375, PMID 39648617, PMID 39715475, PMID 39982105, PMID 42129417, PMID 1027738, PMID 16930838, PMID 17405970, PMID 17520794, PMID 17964164, PMID 19793343, PMID 22920541, PMID 23104993, PMID 24401940, PMID 25297013, PMID 27938913, PMID 28641451, PMID 29171818, PMID 29171821, PMID 29800211, PMID 29813147, PMID 29864085, PMID 30112725, PMID 30112726, PMID 30446596, PMID 30651064, PMID 30654835, PMID 31132795, PMID 31291516, PMID 31447685, PMID 31843807, PMID 32008905, PMID 32088351, PMID 32209650, PMID 32631251, PMID 32844740, PMID 33402419, PMID 33590821, PMID 33633187, PMID 33910942, PMID 34171973, PMID 34285349, PMID 34325828, PMID 34407343
2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), K23NS102521 (1), R01AT012228 (1)